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Abstract
 
Psoriasis is a type I–deviated disease characterized by the presence of interferon (IFN)-
 
  
 
and
multiple IFN-related inflammatory genes in lesions. Because interleukin (IL)-23 is now recog-
nized to play a role in the recruitment of inflammatory cells in a T helper cell (Th)1-mediated
disease, we examined psoriasis skin lesions for production of this newly described cytokine. IL-23
is composed of two subunits: a unique p19 subunit and a p40 subunit shared with IL-12. We
found a reliable increase in p19 mRNA by quantitative reverse transcription polymerase chain
reaction in lesional skin compared with nonlesional skin (22.3-fold increase; P 
 
  
 
0.001). The
p40 subunit, shared by IL-12 and IL-23, increased by 11.6-fold compared with nonlesional skin
(P 
 
  
 
0.003), but the IL-12 p35 subunit was not increased in lesional skin. IL-23 was expressed
mainly by dermal cells and increased p40 immunoreactivity was visualized in large dermal cells
in the lesions. Cell isolation experiments from psoriatic tissue showed strong expression of p19
mRNA in cells expressing monocyte (CD14
 
  
 
CD11c
 
  
 
CD83
 
 
 
) and mature dendritic cell
(DC) markers (CD14
 
  
 
CD11c
 
  
 
CD83
 
 
 
), whereas in culture, the mRNAs for p40 and p19
were strongly up-regulated in stimulated monocytes and monocyte-derived DCs, persisting in
the latter for much longer periods than IL-12. Our data suggest that IL-23 is playing a more
dominant role than IL-12 in psoriasis, a Th1 type of human inflammatory disease.
Key words: cytokines • gene expression • dendritic cell • IL-23 • Th1 cells
 
Introduction
 
IL-23 was found during a genome scan for the IL-6/IL-12
cytokine family (1). IL-23 is a heterodimer, sharing a p40
subunit with IL-12 (1) but having a distinct p19 subunit.
IL-23 binds to IL-12R
 
 
 
1 but not IL-12R
 
 
 
2. The receptor
for this cytokine is heterodimeric and uses a novel second
subunit, IL-23R, which is a member of the hematopoietin
receptor family (2). IL-23 plays a role in type 1–polarized T
cell immune responses. Although IL-12 strongly activates
naive T cells, the initial description of IL-23 reported pref-
erential actions on memory T cells to increase IFN-
 
  
 
pro-
duction and proliferation (1). Mice with p40-null mutations
display reduced IFN-
 
  
 
production and less resistance to a
range of infectious pathogens compared with p35-null mice
(3), suggesting an important role for IL-23 in controlling
bacterial infections. More recent data indicate that IL-23 is a
key cytokine controlling inflammation in peripheral tissues.
In transgenic mice, overexpression of p19 produces inflam-
mation in multiple organs and epithelial tissues, including
the skin (4). In a recent study, the development of experi-
mental autoimmune encephalitis occurred in mice lacking
IL-12, but not in mice with targeted disruption of only IL-23
(5), and IL-23 was shown to be involved in the recruitment
of monocytes into the inflamed nervous system.
Psoriasis vulgaris is a T cell–driven disease, with type I
(IFN-
 
 
 
–producing) T cells predominating in lesional skin
and excess numbers of type 1 T cells in the peripheral cir-
culation (6). Psoriasis affects 
 
 
 
2.6% of the US population
(7) and therefore might be the most common T cell–mediated
inflammatory disease in humans. There is a complex cytokine
network in psoriatic lesions that consists of elevated levels
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of IFN-
 
 
 
, TNF-
 
 
 
, several interleukins (IL-1, IL-2, IL-6,
IL-8, IL-12 [p40 subunit], IL-17, and IL-19), and multiple
chemokines including MIG/CXCL9, IP-10/CXCL10,
I-TAC/CXCL11, and MIP3
 
 
 
/CCL20 (8). A central role
for IFN-
 
  
 
as an inflammatory regulator is suggested from
array-based gene expression studies that identify increased
expression of STAT1 and more than 20 genes controlled by
this transcription factor (9–11). IL-12, a 70-kD heterodimer
formed from p40 and p35 subunits, also has the ability to
stimulate IFN-
 
  
 
production from T cells. Previously, IL-12
was thought to contribute to the type 1 T cell bias in psori-
atic lesions because the p40 subunit is strongly up-regulated
(12, 13) and because IL-12 receptor subunits (IL-12R
 
 
 
1
and IL-12R
 
 
 
2) are also up-regulated (13). However, we
were puzzled by the failure to detect up-regulation of
mRNA for the IL-12 p35 subunit in psoriasis lesions (13).
Because the p40 subunit of IL-12 is shared with IL-23 (as is
the 
 
 
 
1 receptor subunit), we might have incorrectly as-
signed p40 overexpression to IL-12 rather than IL-23.
Accordingly, we studied expression of p19, the defining
subunit for IL-23, in skin lesions of psoriasis vulgaris. We
report consistent large increases in mRNAs encoding IL-23
subunits p19 and p40, but not p35 in psoriatic lesions. We
visualized p40 protein in dendritic profiles within the der-
mis and showed that p19 was enriched in monocytes and
DCs stimulated in the dermis and in culture. Therefore,
IL-23 could be a key inflammatory cytokine in type
1–deviated human autoimmune and inflammatory diseases.
 
Materials and Methods
 
Subjects.
 
After obtaining informed consent, 22 adults with
chronic plaque-type psoriasis had both lesional and nonlesional
skin biopsies. The patients had active, untreated skin lesions. Bi-
opsies were stored in liquid nitrogen until analysis.
 
RNA Isolation.
 
The biopsies were processed using the
QIAGEN RNeasy kit. Using a rotor-stator tissue homogenizer
(saw-tooth rotor; PowerGen 700), frozen specimens were ho-
mogenized in buffer (RLT; QIAGEN) for 30–60 s and spun in a
microcentrifuge for 3 min at room temperature to pellet debris.
The supernatant was loaded onto a QIAGEN minicolumn and
spun for 15 s at high speed. A series of washes and DNase diges-
tion was followed by final elution of RNA from the column us-
ing 30 
 
 
 
l RNase-free water (Sigma-Aldrich). RNA was quanti-
tated by UV spectrophotometry.
 
TaqMan RT-PCR Quantitation of mRNA.
 
The primers and
probes for the TaqMan RT-PCR assays for IL-12 p40, p19, and
p35 were generated using the Primer Express algorithm version 1.0
from published sequences (National Center for Biotechnology In-
formation). All primers and probes were synthesized by Applied
Biosystems-PerkinElmer. RT-PCR reactions were performed ac-
cording to the manufacturer’s directions (EZ PCR Core Reagents;
TaqMan and Applied Biosystems). We used an Applied Biosystems
PRISM 7700 thermal cycler for 2 min at 50
 
 
 
C, 30 min at 60
 
 
 
C, 5
min at 95
 
 
 
C, and 40 cycles of 15 s at 95
 
 
 
C followed by 60 s at
60
 
 
 
C. The human acidic ribosomal protein gene (hARP), a house-
keeping gene, was used to normalize each sample and each gene.
The data were analyzed with Sequence Detection Systems version
1.7 software. Human IL-12 p40 (sequence data available from Gen-
Bank/EMBL/DDBJ under accession no. AY008847) forward
primer: ACGGACAAGACCTCAGCCAC; reverse primer: GGG-
CCCGCACGCTAA; fluorescent probe: TCATCTGCCGCAA-
AAATGCCAGC. Human IL-12 p35 (sequence data available from
GenBank/EMBL/DDBJ under accession no. AF404773): forward
primer: CCACTCCAGACCCAGGAATG; reverse primer: GAC-
GGCCCTCAGCAGGT; fluorescent probe: TCCCATGCCT-
TCACCACTCCCAA. Human IL-12 p19 (sequence data available
from GenBank/EMBL/DDBJ under accession no. NM_016584)
forward primer: GAGCCTTCTCTGCTCCCTGAT; reverse
primer:  AGTTGGCTGAGGCCCAGTAG; fluorescent probe:
CCTGTGGGCCAGCTTCATGCCT. Murine IL-12 p40 (se-
quence data available from GenBank/EMBL/DDBJ under acces-
sion no. NM008352) forward primer: ACATCTACCGAAGTC-
CAATGCA; reverse primer: GGAATTGTAATAGCGATCC-
TGAGC; fluorescent probe: TGCACGCAGACATTCCCG-
CCT. Human hARP (sequence data available from GenBank/
EMBL/DDBJ under accession no. NM_001002) forward primer:
CGCTGCTGAACATGCTCAA; reverse primer: TGTCGAA-
CACCTGCTGGATG; fluorescent probe: TCCCCCTTCTC-
CTTTGGGCTGG. All probes were conjugated with 6-FAM
(dye) at the 5
 
 
 
-end and TAMRA (quench) at the 3
 
 
 
-end (Applied
Biosystems).
 
Statistical Analysis.
 
Paired Student’s 
 
t 
 
test was used to com-
pare lesional and nonlesional gene expression levels. Bonferroni
correction was performed on multivariate calculations of p-values
for p19, p35, and p40 gene expression.
 
DC Generation and Maturation.
 
Mononuclear cells were iso-
lated by density gradient centrifugation using Ficoll (Amersham
Biosciences). Monocytes (purity 
 
 
 
95%) were obtained and cul-
tured to mature DCs as previously described (14).
 
Immunohistochemistry.
 
Monoclonal mouse anti–human anti-
bodies to IL-12 p40 were obtained from R&D Systems (clone
31052.11). Binding of the mouse antibody was detected in skin
samples using biotinylated horse anti–mouse IgG and an avidin–
biotin complex used with a peroxidase visualization reaction ac-
cording to the manufacturer’s directions (Vectastain ABC elite;
Vector Laboratories).
 
Split Skin Tissue Culture.
 
Shaved skin biopsy of lesional skin
in two patients was obtained by scalpel to include an area of 
 
 
 
2
cm
 
2
 
. The biopsy was placed in tissue culture medium (RPMI
1640, Hepes 10 mM) containing 0.5% dispase and incubated at
4
 
 
 
C overnight. The dermis was separated from the epidermis by
forceps. For the RT-PCR assay of epidermis versus dermal p19
and p40 expression (see Fig. 2), the tissues were rinsed with PBS
and then homogenized after separation. For the isolation of in-
flammatory cells from the dermis (see Fig. 3), the dermis was
washed with PBS and then cultured (RPMI 1640 supplemented
with 5% normal human serum, 10 
 
 
 
g/ml gentamicin, and 10
mM Hepes) for 2 d. The inflammatory cells leaving the intact
dermis were then collected and processed for total RNA.
 
Dermal Cell Purification.
 
Cells emigrating from 48-h dermis
cultures were captured by positive selection for CD1a, CD3,
CD11c, CD68, and CD83 using magnetic beads (Pan Mouse IgG
kit; Dynal) covalently attached to anti–mouse IgG F
 
c
 
. These were
coated according to the manufacturer’s protocol with a mouse
IgG antibody to a cell surface antigen (1 
 
 
 
g antibody/25 
 
 
 
l or
10
 
7 
 
beads). The antibody to CD3 was from Orthoclone
 
®
 
, Ortho
Biotech, and the others were from Becton Dickinson. Mouse
IgG isotype control Ab was provided by Protein Design Labs.
The psoriatic dermal cells were split into 1-ml aliquots and incu-
bated with 500 
 
 
 
l of the appropriate antibody-coated magnetic
bead. Cells attached to the beads were separated from nonat-
tached cells by magnet and placed in RLT buffer with 
 
 
 
-mercap- 
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toethanol for p19 and p40 mRNA analysis, whereas unbound
flow-through cells were verified by flow cytometry for depletion
of the targeted cell type.
 
Online Supplemental Material.
 
The supplemental material de-
scribes gene transduction studies to verify the primer-probe set
used for p19 amplification and detection by RT-PCR (TaqMan).
Table S1 and Supplemental Results are available at http://
www.jem.org/cgi/content/full/jem.20030451/DC1.
 
Results
 
Gene Expression Studies.
 
The expression of p40, (IL-23)
p19, and (IL-12) p35 was determined in lesional and nonle-
sional skin of 22 psoriasis patients (Fig. 1). The values ob-
tained for each gene were normalized to the housekeeping
gene hARP. To confirm that our primer/probe set correctly
identified expression of p19 mRNA, we used recombinant
adenovirus-transduced cell lines (see Table S1, which
is available at http://www.jem.org/cgi/content/full/jem.
20030451/DC1). Expression of p19 mRNA was increased
in all 22 lesional skin biopsies (22-fold mean increase; P 
 
 
 
9 
 
  
 
10
 
 
 
7
 
) as was p40 mRNA (12-fold mean increase; P 
 
 
 
4.8 
 
  
 
10
 
 
 
7
 
). The expression of p35 mRNA was more vari-
able, but the mean values for paired lesional and nonlesional
skin samples did not differ significantly (P 
 
  
 
0.153).
 
Immunohistochemical Studies of IL-12p40 Expression.
 
Be-
cause an antibody to the p19 subunit is presently not avail-
able, we used a p40-reactive antibody to localize potential
cells that might synthesize the IL-23 heterodimer in psoriasis
lesions. Intensely positive staining cells were noted in the
papillary dermis of lesional skin and were dendritic in ap-
pearance (Fig. 2 D). Little background staining was seen with
an isotype control antibody in uninvolved or lesional skin
(Fig. 2, A and B). The anti-p40 monoclonal antibody pro-
duced a variable degree of staining in basal keratinocytes of
uninvolved skin, but very few p40-reactive cells were seen in
the dermis of uninvolved skin (Fig. 2 C). Variable degrees of
epidermal staining with the p40 antibody were noted, but
staining of dermal cells was consistent across many different
cases of psoriasis vulgaris. Overall, the staining pattern for
p40 most resembled the staining of DCs in lesions, as de-
tected previously with antibodies to CD83 or CD11c (15).
 
Localization of p19/p40 mRNA Expression Mainly to Der-
mal Cells.
 
Comparison of gene expression in dispase-sepa-
rated epidermis and dermis from lesions showed that most of
the mRNA for p19 and p40 was contained in dermal cells
(Fig. 3 A). We then used immunomagnetic beads to enrich
specific populations of leukocytes isolated from the dermis of
psoriasis lesions (Fig. 3 B). A low level of p19 mRNA was
detected in cells isolated with anti-CD3 beads, whereas
higher levels were measured in cells selected with anti-CD83,
anti-CD11c, and anti-CD68 beads (Fig. 3 B). To characterize
the cells isolated by antibody-coated magnetic beads, we as-
sayed the unbound (flow-through) fraction for depletion of
HLA-DR
 
  
 
and CD83
 
  
 
or CD3
 
  
 
cells (Fig. 3 D). Using two
color flow cytometry and gating parameters appropriate for T
cells and DCs (Fig. 3 C, R1 and R2, respectively), we found
that CD11c depletion increased the relative concentration of
CD83
 
  
 
cells (68%), but decreased the frequency of CD14
 
 
 
cells, as expected if many of the CD11c
 
  
 
cells were mono-
cytes (Fig. 3 D). Analogously, CD83 depletion decreased the
relative concentration of CD83
 
  
 
cells in the flow through
(Fig. 3 D, 14%), but did not deplete CD14
 
  
 
cells (not de-
picted), as expected if these cells were mature DCs. CD3 de-
pletion resulted in only a minor increase in CD83
 
  
 
cells in
the flow through (Fig. 3 D, 49%). CD3
 
  
 
cells (gate R1) were
depleted only with CD3 antibody beads (Fig. 3 D, bottom).
Figure 1. Expression of p19, p40, and p35 mRNA in paired samples of
uninvolved and lesional skin from psoriasis patients.  , indicates the
arithmetic mean for each type of specimen and is not connected by a line.
A line connects the paired samples taken from each patient’s nonlesional
and psoriatic skin. Data is presented as the ratio of PCR yield, in pico-
grams, of p19 (A), p40 (B), and p35 (C) normalized to the yield of hARP.
Note the logarithmic scale of the abscissa. 
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By immunohistochemical and FACS
 
® 
 
staining of dermal cells
from other biopsies, large increases in presumptive monocytes
(CD11c
 
  
 
CD14
 
  
 
CD83
 
 
 
) and mature DCs (CD11c
 
 
 
CD14
 
  
 
CD83
 
 
 
) were detected in active psoriasis lesions
compared with unaffected skin of the same patients.
 
Strong and Sustained Expression of p19 and p40 in Mature
DCs.
 
To further examine the control of IL-12 and IL-23
expression in monocytes and DCs, we used a standard pro-
cedure to generate DCs from peripheral blood monocytes
using 4 d of culture in GM-CSF and IL-4 to produce im-
mature DCs and a cytokine cocktail to mature the DCs
(14). Fig. 4 displays quantitative expression of p19, p40, and
p35 mRNAs in monocytes and in monocyte-derived DCs
at various times after the addition of our maturation stimu-
lus, and essentially parallels results seen with CD40L-stimu-
lated DCs (1). Monocytes (
 
 
 
144 h), as well as monocytes
Figure 2. Immunohistochemical
localization of p40 in psoriatic
skin. The four panels are from
frozen sections of human skin
from psoriasis patients. A and B
are IgG isotype controls in unin-
volved and lesional skin, respec-
tively. C and D are stained with
mouse anti–human IL-12p40 as
indicated. The arrow indicates
morphology consistent with DCs.
The color represents 3-amino-9-
ethylcarbazole deposition at the
site of antibody binding. Melanin
appears in A as dark stain in the
basal cell layer.
 
tional 2 d at 37
 
 
 
C and the cells exiting the cultured dermis (B, C, and D)
were collected for subsequent quantitative gene expression for p19 using
immunomagnetic beads coated with antibodies to CD3, CD11c, or
CD83. In each case, two cell populations were obtained: one adherent to
the beads expressing CD83, CD11c, or CD68 (B), and one nonadherent
(C and D) that was used to monitor the depletion by FACS
 
®
 
. For the latter,
flow-through cells were analyzed for the presence of HLA-DR and
CD83. (B) Total RNA was isolated and gene expression for p19 was assayed
using TaqMan chemistry as described in Materials and Methods. Data are
from one representative experiment. A repeat run produced almost identical
results. (C, left) Side and forward scatter plots and gating (R1 for lymphocytes
and R2 for DCs) for subsequent panels. (C, middle and C, right) Isotype
controls. Cells depleted by isotype control (D, top, panel 1), anti-CD11c
(D, top, panel 2), anti-CD83 (D, top, panel 3), and anti-CD3 (D, top,
panel 4). Note that percentages represent upper right quadrant cell count
(HLA-DR
 
  
 
CD83
 
 
 
) as percent of total. Each panel has a plot of forward
scatter versus CD3
 
  
 
to demonstrate additional specificity of the depletion.
 
Figure 3.
 
p19 and p40 gene expression in dispase split skin and dermally
derived inflammatory cells. (A) Dermis from psoriasis lesions has greater
p19 and p40 mRNA than epidermis. The data are from one representative
experiment. A repeat run produced almost identical results. RNA was
isolated from dispase split lesional skin taken from psoriatic plaques from
two patients. RT-PCR for the p19 and p40 genes was performed on the
epidermis and dermis and gene expression levels are shown relative to the
hARP gene. In two other patients, the dermis was cultured for an addi- 
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cultured in GM-CSF and IL-4 to stimulate the differentia-
tion of immature DCs (0 h), expressed relatively low levels
of p19 mRNA and virtually undetectable levels of p40
mRNA along with gradually decreasing levels of p35
mRNA. However, p19 mRNA was increased up to 10-fold
in freshly isolated monocytes by the addition of TNF-
 
  
 
or
the maturation cocktail (IL-1
 
 
 
, IL-6, TNF-
 
 
 
, and PGE2)
for 6–24 h, but p40 and p35 mRNA were not significantly
induced by these stimuli (not depicted). For immature DCs,
however, the addition of the maturation cocktail produced
a rapid increase in mRNA for p19, p40, and p35 subunits,
but with differing kinetics. Relative to immature DCs,
there was at least a 50-fold increase in p19 and p40 mRNA
in maturing and mature DCs. The up-regulation of these
IL-23 subunits was sustained over the full 48-h maturation
period and was highest in fully mature CD83
 
  
 
DCs. In con-
trast, there was a rapid increase in p35 mRNA 6 h after giv-
ing the maturation stimulus, but the levels declined by
5–10-fold by 24 and 48 h. Other responses during DC mat-
uration (6, 24, and 48 h) included strong up-regulation of
DC-LAMP mRNA and decreased expression of DC-SIGN
mRNA, and induction of CD83 protein at 48 h.
 
Discussion
 
Accumulating evidence supports the role of type 1 T cells
and IFN-
 
  
 
in the pathogenesis of psoriasis (8). Individual
components of the type 1 pathway, both cellular and cyto-
kine, are therapeutic targets in psoriasis. The development
of Th1-type helper cells can be driven by IL-12 (1). We and
others have previously reported that IL-12 p40 mRNA is
elevated in psoriasis (12, 13), but we were perplexed by the
failure to find elevated IL-12 p35 mRNA in diseased skin.
We would now like to suggest that IL-23, not IL-12, is a
key cytokine in psoriatic skin lesions based on the finding
that p19 and p40, but not p35 mRNA, are overexpressed.
We believe that this is the first report that IL-23 p19 is
up-regulated in a human disease. Recent reports have dem-
onstrated a role for this novel cytokine in enhanced cutane-
ous immunity in a transgenic mouse model (16) and in in-
flammatory disorders such as experimental autoimmune
encephalitis in a mouse model (5). With our observation
that IL-23 is up-regulated in psoriatic skin, it became neces-
sary to identify the cell of origin. The current lack of an an-
tibody to p19 currently hampers this work. However, the
reactivity of large cells in psoriasis lesions with antibodies
specific for p40 suggests that IL-23 (given the failure to find
increased IL-12 p35 mRNA in lesional skin) is likely to be
actively synthesized in psoriasis lesions (12) and then act lo-
cally on cells that have up-regulated IL-12 receptors (13). In
this study, we also found that IL-23 p19 and p40 mRNA
were strongly up-regulated in monocyte-derived human
DCs after encountering a maturation stimulus, and that p19
mRNA was strongly expressed in cells bearing both imma-
ture and mature DC surface markers in psoriasis lesions
(CD11c
 
  
 
CD14
 
  
 
CD83
 
  and CD83 ). The sustained ex-
pression of IL-23 subunits in cultured fully mature DCs con-
trasted sharply with the transient expression of p35 mRNA
in maturing DCs. Of the cells known to express IL-23 p19,
only macrophages and DCs concurrently express p40 and
are known to express functional IL-23 protein. Monocytic
and DC lines have previously been identified as IL-23 pro-
ducers, whereas mature human DCs have been shown to se-
crete IL-23 protein (1, 17). Thus, it seems that the mRNA
and protein subunits of IL-23 are coordinately up-regulated
in producing cells. One of the cellular features of psoriasis
skin lesions is a marked increase in mature CD83  DCs,
whereas uninvolved skin contains mostly immature Langer-
hans cells and dermal DCs (15, 18, 19). Based on p40 im-
munostaining, infiltrating mononuclear leukocytes are the
likely source of IL-23 in lesions. Given that p35 mRNA is
expressed only transiently in activated DCs and p35 mRNA
is not elevated in lesional skin, IL-12 is likely to be expressed
at lower levels than IL-23 in psoriatic lesions. Adoptive
transfer experiments have clearly established leukocytes as
the chief source of IL-23 in inflammatory lesions (4).
It is possible that both IL-12 and IL-23 have a role in
psoriatic skin disease. However, the work in murine exper-
imental autoimmune encephalitis indicates that IL-23 is
critical for a monocyte-rich inflammatory response. Ex-
pression of IL-23 may also drive increased production of
IL-17 in affected skin (20). IL-17 has been reported to in-
crease the expression of iNOS (21), a gene that is consis-
tently overexpressed in psoriasis lesions (13). In model sys-
tems, IL-23 acts on DCs to allow for the induction of
immunity to otherwise tolerogenic peptides (22), so poten-
Figure 4. Expression of p19, p40, and p35 mRNA in monocyte-derived
DCs. Monocytes were placed in culture at  144 h, differentiated to im-
mature DCs, and then stimulated beginning at 0 h with TNF- , IL-1 ,
IL-6, and PGE2 for the stated amount of time. The data bars (open and
solid) represent relative gene expression of p19 (A), p40 (B), and p35 (C)
from two separate experiments. Note differing abscissa scales.Cytokines in Psoriasis 130
tially its expression could contribute to abnormal antigenic
recognition of skin-related antigens in psoriasis. Interest-
ingly, a recent report identified skin inflammation in a
skin-targeted p40 transgenic overexpressor as due to IL-23
production, but not IL-12 production, and there was a
marked increase in the abundance of mature DCs in these
lesions associated with increased IL-23 levels (16). In sum-
mary, IL-23 antagonists might be the most appropriate
treatment for inflammatory skin diseases like psoriasis.
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